Hypertriglyceridemia.

Alan Chait

Journal: Endocrinology and metabolism clinics of North America 2022;51(3):539-555

PMID: 35963627

Full Text on Elsevier Science View on PubMed

Abstract

Mild to moderate hypertriglyceridemia usually results from multiple small-effect variants in genes that control triglyceride metabolism. Hypertriglyceridemia is a critical component of the metabolic syndrome but can also occur secondary to several other conditions or drugs. Hypertriglyceridemia frequently is associated with an increased risk of cardiovascular disease (CVD). Statins are the mainstay of CVD prevention in hypertriglyceridemia, but eicosapentaenoic ethyl esters should be added in very-high-risk individuals. Although fibrates lower triglyceride levels, their role in CVD prevention remains unclear. Familial partial lipodystrophy is another relatively rare cause, although its true incidence is unknown.

Address: Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, 850 Republican, Box 358062, Seattle, WA 98109, USA. Electronic address: [email protected].

DOI: 10.1016/j.ecl.2022.02.010

Link outs

Free resources

Medical:

https://medlineplus.gov/metabolicsyndrome.html

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-1105

Subscription / membership required

Full Text Sources:

MeSH Terms: Cardiovascular Diseases, Humans, Hypertriglyceridemia, Metabolic Syndrome, Triglycerides